Weight Loss/GLP-1 Patient Acquisition for Prescribers

You’re seeing it in your practice already: patients on Seroquel who’ve gained 40 pounds, antidepressant users asking about Ozempic, and colleagues wondering if they should jump into the weight-loss gold rush. The question isn’t if GLP-1 medications are changing healthcare — it’s whether psychiatric providers should be prescribing them, and whether adding weight management makes sense for your practice growth.

Here’s the reality: 8-10% of Americans are currently using GLP-1 medications, with another third expressing interest. That’s roughly 35-40 million potential patients actively searching for providers who can prescribe these medications. Meanwhile, psychiatrists and psychiatric nurse practitioners are uniquely positioned at the intersection of mental health and metabolic health — two systems that are, as one metabolic psychiatrist puts it, ‘inseparable.’

But before you start advertising weight-loss services, let’s talk through the clinical rationale, the business case, and what actually works when expanding into this space.

The Clinical Case: Why This Actually Makes Sense for Psych Providers

The Medication-Induced Weight Gain Problem

If you prescribe antipsychotics, mood stabilizers, or even certain antidepressants, you’ve created the problem you’re now being asked to solve. Medications like olanzapine, quetiapine, and mirtazapine can cause 10-30+ pound weight gains, increasing patients’ risk of diabetes, cardiovascular disease, and — critically — medication non-adherence because they hate how they look and feel.

Traditional advice (‘try metformin, exercise more’) often fails. Patients drop their psychiatric medications because the weight gain feels worse than their original symptoms. This is where GLP-1 receptor agonists enter the picture as a legitimate medical solution, not a cosmetic quick-fix.

The Evidence: GLP-1s Are Psychiatrically Safe (and Maybe Helpful)

The data on GLP-1 medications in psychiatric populations is increasingly reassuring. Studies show that semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound):

• Do NOT increase depression or suicidal ideation (early concerns have been debunked)
• May actually IMPROVE mood and quality of life in patients with obesity
• Reduce food cravings and obsessive eating thoughts — potentially helpful in binge eating disorder
• Improve inflammatory markers and metabolic health, which correlates with better mental health outcomes

One psychiatrist specializing in metabolic psychiatry notes: ‘These medications affect neurotransmitter function, gut-brain signaling, and inflammation — all systems that directly impact mood, anxiety, and cognitive function. Treating metabolic illness can improve mental health outcomes, and vice versa.’

The Integrated Care Argument

Forward-thinking psychiatrists are beginning to practice what’s being called ‘metabolic psychiatry’ — acknowledging that you cannot separate brain health from metabolic health. If a patient develops obesity from your prescribed medication, addressing that obesity isn’t outside your scope — it’s completing the circle of care.

This isn’t about becoming a bariatric specialist. It’s about managing the full consequences of the medications you already prescribe, and offering patients a comprehensive solution instead of referring them into a fragmented system where they’ll likely get lost.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Business Reality: Understanding Patient Acquisition Economics

Now let’s talk numbers, because adding a service line only makes sense if the economics work.

What Patient Acquisition Actually Costs

The weight-loss telehealth market hit $6.9 billion in 2023 and continues growing at 8%+ annually. That explosive growth has attracted dozens of well-funded startups spending aggressively on patient acquisition. Here’s what that competition means for you:

If you try to build your own patient pipeline through DIY marketing:

• Google Ads for weight loss keywords cost $15-40+ per click, with conversion rates typically under 5%. Realistically, you’ll spend $200-400+ per booked patient once you factor in wasted clicks, optimization, and no-shows from cold leads.
• SEO takes 6-12 months of consistent content creation and technical optimization before generating meaningful organic traffic. Most solo providers don’t have the expertise or patience for this.
• Directory listings like Psychology Today or Zocdoc charge monthly fees ($100-300+) AND you’re competing with hundreds of other providers on the same page. Zocdoc additionally charges per booking ($35-100+).
• All of this requires staff time to qualify leads, handle inquiries, manage campaigns, and follow up — costs that rarely get factored into the ‘cost per patient’ calculation.

When you add it all up honestly — agency fees, ad spend, staff time, failed campaigns, and the 6-12 month ramp-up before any meaningful ROI — acquiring psychiatric patients through traditional marketing typically costs $200-500+ per patient, not the unrealistic ‘$30-50’ figures sometimes quoted by marketing agencies who only count their click costs.

The Platform Economics Alternative

This is where platforms using a pay-per-appointment model (like Klarity Health) present a different economic equation:

Instead of:

• $3,000-5,000/month on marketing with uncertain results
• Months of testing and optimization
• Hiring or contracting marketing expertise
• Building telehealth infrastructure
• Managing patient acquisition staff

You get:

• No upfront marketing spend
• Pre-qualified patients already matched to your specialty and availability
• Payment only when you actually see patients (standard listing fee per new patient)
• Built-in telehealth infrastructure included
• Both insurance and cash-pay patient flow

The value proposition isn’t just about cost — it’s about risk elimination. With traditional marketing, you’re gambling $30,000-60,000 annually on campaigns that might not work. With a pay-per-appointment model, you only pay when you generate revenue. That’s guaranteed ROI versus a marketing experiment.

Average Patient Economics in Weight Management

To understand if the numbers work, consider lifetime value. Real-world data shows:

• Average GLP-1 patient spends $600-800 annually on provider services (excluding medication costs)
• This covers approximately 4-6 visits at $100-150 per visit for cash-pay, or billable telehealth consults for insured patients
• Many patients continue for 12-18 months if they see results and can afford medication
• About 50% discontinue within the first year (due to cost, side effects, or achieving goals)

If you’re paying $200-300 to acquire a patient through a platform model, and that patient generates $600-1,200 in revenue over their treatment course, you’re looking at a 2:1 to 4:1 return. That’s sustainable economics for practice growth.

The key is patient retention and upselling additional services (therapy for emotional eating, ADHD medication management, comprehensive psychiatric care for comorbid conditions). The initial weight-loss consultation becomes a gateway to a longer-term therapeutic relationship.

State-Specific Opportunities and Barriers

The ability to grow a weight-loss practice varies significantly by state due to scope of practice laws, telehealth regulations, and insurance coverage differences.

California: NP Independence + Medicaid Coverage = Growth Opportunity

As of January 2026, California nurse practitioners with 3+ years experience can practice independently without physician supervision in any setting. This means psychiatric NPs can launch their own weight-loss telehealth practices without physician oversight.

Additionally, California Medicaid (Medi-Cal) covers GLP-1 obesity medications — one of only 14 states offering broad coverage. Medi-Cal spent $1.4 billion on GLP-1s in 2024, reflecting massive patient uptake. For providers, this means you can serve not just cash-pay patients but also Medi-Cal enrollees, significantly expanding your potential patient base.

The challenge? California has the highest concentration of venture-funded telehealth startups and fierce competition in urban markets. You’ll need strong differentiation — emphasizing your psychiatric expertise and integrated mental health approach can help you stand out.

Texas: High Demand, But Collaboration Required

Texas has one of the highest obesity rates in the U.S. (35%+ of adults), creating enormous demand for weight-loss services. Telehealth is well-established and you can prescribe to patients statewide with a Texas license.

The limitation: Texas requires NPs to have physician collaboration agreements. If you’re a psychiatric NP wanting to add weight management, you’ll need an MD partner (which adds cost and complexity). However, many physicians are open to these arrangements for a monthly fee or revenue split.

Texas Medicaid offers only partial coverage for obesity medications, meaning most patients will be cash-pay or using manufacturer assistance programs. This skews your patient demographics toward higher-income individuals who can afford out-of-pocket medication costs.

Florida: Telehealth Access, But Coverage Gaps

Florida offers unique out-of-state telehealth registration, allowing licensed providers from other states to treat Florida patients without a full Florida license. This expands your potential market significantly if you’re licensed elsewhere.

However, Florida Medicaid does not cover GLP-1 medications for obesity — only for diabetes. This means you’ll primarily attract commercially insured or cash-pay patients. Given Florida’s large retiree population and strong aesthetic medicine culture (especially in South Florida), there’s robust demand, but expect patients to be cost-conscious given limited insurance support.

New York: Independent Practice, But No Medicaid Coverage

New York allows experienced NPs (3,600+ hours) to practice independently, making it easy for psychiatric NPs to add weight management services without physician oversight.

The market challenge: New York Medicaid excludes coverage for weight-loss medications, limiting access for lower-income populations. However, New York City and surrounding areas have high concentrations of commercially insured, health-conscious consumers willing to pay for weight management services. Position yourself in the wellness/integrated care space to attract this demographic.

Pennsylvania: Medicaid Support, But NP Restrictions

Pennsylvania presents an interesting mix: high obesity rates (33-35%), generous Medicaid coverage for GLP-1 medications, but restricted NP practice requiring physician collaboration.

The opportunity: Pennsylvania Medicaid spent $298 million on GLP-1s in 2024, second only to California. This indicates strong state support and patient access. If you can serve Medicaid patients (or help patients navigate coverage), you can tap into a large, underserved population.

For NPs, you’ll need to partner with a physician, but many family medicine and internal medicine docs are open to collaborative arrangements, especially if you’re bringing patient volume.

Illinois: NP Independence After Experience

Illinois grants full practice authority to NPs after 4,000 hours of clinical experience plus continuing education requirements. This makes it NP-friendly after an initial collaborative period.

The limitation: Illinois Medicaid does not yet cover obesity medications specifically (2024 legislation was introduced but not yet passed). You’ll primarily serve commercially insured or cash-pay patients, focusing on Chicago’s urban market and suburban populations with wellness budgets.

Federal Controlled Substance Rules: What You Need to Know

If your weight-loss protocol includes controlled substances (like phentermine for appetite suppression), pay attention to federal DEA rules.

The DEA’s temporary COVID-era allowance for prescribing controlled substances via telehealth without an in-person exam is set to expire December 31, 2025. After that, new patients will require at least one in-person evaluation before you can prescribe Schedule II-V controlled substances via telehealth.

Important clarification: GLP-1 medications (semaglutide, tirzepatide) are NOT controlled substances. You can prescribe them via telehealth in any state without in-person exam requirements, as long as you follow state practice standards.

If you’re considering adding phentermine (Adipex) to your protocols, plan for either:

• An initial in-person consultation requirement after January 1, 2026
• Partnering with local physicians who can conduct the in-person exam
• Sticking exclusively to non-controlled medications (GLP-1s, metformin, etc.)

What Weight-Loss Patients Are Actually Searching For

Understanding patient search behavior is critical for visibility and conversion.

Top Search Queries:

• ‘How to get Ozempic for weight loss’ (113,000+ monthly searches)
• ‘Ozempic for weight loss’
• ‘Wegovy near me’
• ‘GLP-1 weight loss doctor online’
• ‘Ozempic prescription online’

Notice what’s missing? Nobody’s searching ‘psychiatrist for weight loss’ yet. Patients are searching for medications and outcomes, not provider types.

What This Means for Your Marketing:

1. Content Strategy: Create blog posts and landing pages answering these specific queries. Examples: ‘How Psychiatrists Can Help with Medication-Induced Weight Gain,’ ‘Getting GLP-1 Prescriptions: What to Expect,’ ‘Managing Weight While on Psychiatric Medications.’

2. Local SEO: Optimize for ‘[Your City] weight loss doctor’ and ‘[Your City] GLP-1 clinic’ even if you’re primarily offering telehealth — many patients still search locally first.

3. Emphasize Convenience: Today’s weight-loss consumers expect ‘Amazon-like’ service. Highlight: same-day appointments available, 100% online visits, prescriptions sent to your preferred pharmacy within 24 hours.

4. Address Cost Concerns: Many patients search ‘cheap Wegovy alternative’ or ‘compounded semaglutide.’ If you work with compounding pharmacies or can help patients navigate insurance coverage, make that prominent in your messaging.

5. Privacy Matters: Some patients search ‘discreet weight loss clinic’ or ‘telemedicine weight loss no judgment’ — they’re uncomfortable with in-person weigh-ins or previous negative experiences. Position telehealth as a judgment-free, private solution.

Smart Marketing Strategies That Actually Work

The GLP-1 weight-loss market is crowded and competitive, with pharmaceutical companies and telehealth giants spending millions on Google Ads. Here’s how to compete smartly without burning your marketing budget:

1. Lead With Your Differentiator: Integrated Mental Health Support

Most weight-loss clinics are staffed by nurse practitioners or physician assistants following protocols. Very few offer integrated mental health care. Your psychiatric expertise is a massive competitive advantage:

• ‘Weight loss treatment from a psychiatrist who understands the mental health side of eating, body image, and medication effects’
• ‘Comprehensive care for patients dealing with both weight and mood — because they’re connected’
• ‘Specialized in helping patients who gained weight from psychiatric medications’

This positioning attracts patients who’ve failed at other programs because nobody addressed their emotional eating, food anxiety, or medication-related metabolic issues.

2. Content Marketing Beats Paid Ads on ROI

Data shows content marketing generates 3× more leads than paid ads, at 62% lower cost. Instead of spending $5,000/month on Google Ads competing with Hims and WeightWatchers, invest in:

• Weekly blog posts answering patient questions: ‘Do GLP-1 medications cause depression?’ ‘How to manage nausea on Ozempic,’ ‘Wegovy vs. Ozempic: What’s the difference?’
• Video content explaining how treatment works, what to expect, patient success principles (not before/after photos, which can be ethically tricky)
• Email sequences for newsletter subscribers offering obesity education, medication updates, and patient testimonials

This builds organic traffic over time and establishes you as the trusted expert — not just another clinic advertising aggressively.

3. Email Marketing: The Highest ROI Channel

Email marketing delivers an average $42 return for every $1 spent — higher than any other digital channel. Build an email list by offering:

• Free guide: ‘Understanding GLP-1 Medications: A Psychiatrist’s Guide’
• Quiz: ‘Is Medical Weight Loss Right for You?’
• Webinar: ‘How to Lose Weight While Managing Depression and Anxiety’

Then nurture that list with weekly educational content, patient stories (with permission), and clear calls-to-action to book a consultation. Many patients won’t convert immediately, but consistent email nurture keeps you top-of-mind when they’re ready.

4. Leverage Patient Reviews and Social Proof

Weight-loss is outcome-driven. Prospective patients want to see proof that your approach works. Encourage satisfied patients to:

• Leave Google reviews (mention ‘Dr. Smith helped me lose 30 pounds while managing my depression’)
• Share testimonials (written or video, with consent and HIPAA compliance)
• Participate in case studies (de-identified: ’45-year-old patient lost 15% body weight in 6 months with integrated psychiatric and weight management care’)

Be cautious with before/after photos — many states have strict rules, and the FDA scrutinizes weight-loss advertising. Stick to factual testimonials emphasizing the care experience, not guaranteed results.

5. Use Paid Ads Strategically, Not as Your Only Strategy

Don’t abandon paid advertising entirely, but use it intelligently:

• Target long-tail keywords: Instead of bidding on expensive ‘Ozempic for weight loss’ ($40+ per click), target ‘psychiatrist for weight management [Your City]’ or ‘weight loss for antidepressant users’
• Retargeting campaigns: Use Facebook/Google retargeting to stay in front of people who visited your website but didn’t book
• Lead magnets, not direct booking: Drive ad traffic to a free guide or consultation quiz, capturing emails instead of expecting immediate appointments

Track your cost per acquisition religiously. If you’re spending $500 on ads and acquiring 2 patients, that’s $250 per patient. Is that sustainable given your revenue per patient? Adjust or cut campaigns that don’t hit at least 3:1 ROI.

6. Build Referral Networks

Don’t overlook physician referrals. Many primary care doctors, endocrinologists, and therapists have patients asking about GLP-1s but don’t want to manage them directly. Position yourself as their referral solution:

• Offer lunch-and-learn sessions: ‘New Options for Obesity Treatment: A Psychiatric Perspective’
• Send introduction letters to local PCPs explaining your services
• Create a simple referral process (online referral form, rapid appointment availability)
• Provide feedback to referring providers (with patient consent) so they see you’re a collaborative partner

Word-of-mouth from satisfied patients is also powerful. Weight loss is visible, and people talk. Build systems to request referrals: ‘If you know anyone struggling with weight while on psychiatric medications, we’d love to help them too.’

Key Metrics to Track for Growth

To know if your weight-loss service line is actually growing profitably, track these numbers monthly:

1. New patient inquiries (how many leads from all sources)
2. Conversion rate (what % of inquiries become booked patients)
3. Cost per acquisition (total marketing spend ÷ new patients)
4. Patient lifetime value (average revenue per patient over their treatment course)
5. Retention rate (what % of patients continue beyond 3 months, 6 months, 12 months)
6. ROI by channel (which marketing sources — SEO, ads, referrals — generate the best return)

Aim for at least 3:1 ROI on marketing spend, with 5:1+ being ideal. For example, if you spend $2,000 on marketing in a month and acquire 10 new patients generating $6,000 in revenue, that’s a 3:1 return.

Monitor retention closely. If 70% of patients drop off after month 2, investigate why: Is it medication side effects? Cost? Lack of results? Inadequate follow-up? Improving retention from 30% to 50% can double your revenue without acquiring a single additional patient.

Real Talk: Should You Actually Do This?

Adding weight management to your psychiatric practice isn’t right for everyone. Here’s how to decide:

This makes sense if:

• You already treat patients with medication-induced weight gain or comorbid obesity
• You’re interested in metabolic psychiatry and willing to learn obesity pharmacotherapy
• You want to differentiate your practice and add a high-demand service line
• You’re comfortable with more ‘consumer-driven’ patients (weight-loss clients often behave differently than therapy clients)
• You can commit to proper monitoring, lifestyle counseling, and behavioral support — not just prescribing and moving on

Skip this if:

• You prefer traditional psychotherapy-focused practice
• You’re not interested in managing medication side effects and metabolic monitoring
• You don’t want to deal with insurance challenges around obesity medications
• Your state’s practice laws make it prohibitively difficult (e.g., NP in restricted state without physician partner)
• You’re looking for a quick cash grab without providing comprehensive care

The providers succeeding in this space aren’t treating weight management as a side hustle — they’re integrating it thoughtfully into evidence-based, holistic psychiatric care. They’re taking the time to understand GLP-1 pharmacology, managing side effects carefully, providing behavioral support, and treating the whole patient.

The Bottom Line

Should psychiatrists prescribe GLP-1 medications for weight loss? Clinically, the answer is increasingly yes — especially for patients with psychiatric medication-induced weight gain or comorbid mental health and metabolic conditions. The evidence supports safety, and the practice aligns with integrated, whole-person care.

From a business perspective, the opportunity is real but requires strategy. The weight-loss telehealth market is crowded, patient acquisition is expensive, and you’re competing with well-funded startups. But psychiatric providers have a unique competitive advantage: you can address both the mental and metabolic components of obesity in ways that weight-loss mills cannot.

If you’re going to do this, commit to doing it right:

• Get proper training in obesity medicine and GLP-1 prescribing
• Build systems for patient education, monitoring, and support
• Market smartly, emphasizing your psychiatric expertise and integrated approach
• Use platforms or partnerships that handle patient acquisition efficiently
• Track your economics and ROI carefully

Done well, adding weight management services can:

• Improve outcomes for your existing patients struggling with weight
• Attract new patients seeking comprehensive mind-body care
• Generate sustainable additional revenue (not overnight riches)
• Position you at the forefront of metabolic psychiatry — the future of integrated healthcare

The patients are out there searching right now. The question is whether you’re ready to meet them where they are.

Ready to explore adding weight management to your practice without the upfront marketing risk? Klarity Health connects psychiatric providers with pre-qualified patients seeking comprehensive mental health and metabolic care. You set your schedule, see patients via telehealth, and only pay when you actually provide care — eliminating the gamble of traditional marketing. Learn more about joining Klarity’s provider network.

Frequently Asked Questions

Is it within a psychiatrist’s scope of practice to prescribe GLP-1 medications for weight loss?

Yes. Physicians (MD/DO) can prescribe any FDA-approved medication within their clinical competence, including GLP-1 receptor agonists for obesity. The key is having adequate training in obesity pharmacotherapy, metabolic monitoring, and managing side effects. Many psychiatrists already manage these medications for patients with psychiatric medication-induced weight gain. Psychiatric nurse practitioners’ scope varies by state, but in full-practice states, experienced PMHNPs can prescribe obesity medications within their scope.

Do GLP-1 medications cause depression or increase suicide risk?

Current evidence shows GLP-1 medications do NOT increase depression or suicidal ideation. Early reports prompted FDA investigation, but subsequent large-scale reviews found no causative link. In fact, some studies show GLP-1s may improve mood and quality of life in patients with obesity. As with any medication, monitor patients for mental health changes, but the data is reassuring.

How much can I realistically charge for weight-loss services?

Typical telehealth weight-loss programs charge $50-150 per visit for consults, plus monthly program fees of $30-80 (not including medication costs, which are billed separately through pharmacies). Cash-pay patients average $600-800 annually in provider service fees. Insurance reimbursement varies — some plans cover obesity medicine visits at standard telemedicine rates ($80-120), others don’t. Many successful practices use a hybrid model: insurance billing when possible, cash-pay fee schedules when not covered.

What if patients can’t afford the medications?

This is the biggest barrier to treatment adherence. Options to help patients include: 1) Manufacturer savings programs (Novo Nordisk and Eli Lilly offer co-pay cards for eligible patients, reducing cost to $25-100/month), 2) Compounded semaglutide from pharmacies (significantly cheaper but not FDA-approved — discuss risks/benefits), 3) State Medicaid coverage (if patient qualifies and your state covers obesity drugs), 4) Alternative medications (generic metformin for metabolic support costs $4-10/month). Build relationships with pharmacies offering compounding or help patients navigate manufacturer assistance.

How do I differentiate from all the telehealth startups offering GLP-1s?

Emphasize what they can’t offer: integrated mental health expertise. Most telehealth weight-loss mills are staffed by NPs or PAs following protocols with minimal individualization. You can offer: 1) Treatment for comorbid depression, anxiety, binge eating disorder, 2) Management of psychiatric medication-related weight gain, 3) Behavioral therapy addressing emotional eating and body image, 4) Slower, more individualized dosing strategies (rather than cookie-cutter titration), 5) Comprehensive follow-up instead of ‘prescription mills.’ Market yourself as the provider who treats the whole person, not just writes prescriptions.

What states have the best opportunities for growth in weight-loss telehealth?

States with independent NP practice authority and Medicaid coverage of obesity medications offer the best growth conditions: California, Pennsylvania, and potentially Illinois (if Medicaid coverage expands). States with high obesity rates but restricted NP practice (Texas, Florida) have strong patient demand but require physician collaboration, which adds complexity. States with generous insurance coverage attract patients who can sustain long-term treatment; states without coverage skew toward cash-pay demographics. Consider your license, your competition, and insurance landscape when choosing where to focus growth efforts.

Sources and References

Note: All sources accessed and verified as of February 2026. Providers should consult current state medical board websites for the latest regulations, as telehealth and prescribing rules continue to evolve.

Source:

• https://bask.health/blog/glp-1-weight-loss-persona-marketing#:~:text=movement%20that%20changes%20healthcare
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=consumers%20like%20the%20convenience
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=I%20want%20to%20address%20a,1%20receptor%20agonist%20medications
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=%2A%20GLP,1s%20as%20part%20of%20integrated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=neurotransmitter%20function%20,psychiatric%20care
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=Traditionally%2C%20psychiatrists%20prescribe%20psychiatric%20medications,primarily%20indicated%20for%20metabolic%20conditions
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=Top%20Things%20to%20Know%20About,Weight%20Loss%20Telehealth%20Services
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=Major%20Players%3A%20Digital%20health%20companies,and%20independent%20provider%20practices
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=,independent%20provider%20practices
• https://www.statnews.com/2025/11/18/telehealth-pharma-glp1-partnerships-increase-drug-access-boost-sales/#:~:text=Patients%20searching%20for%20those%20deals,that%20partner%20with%20Novo%20Nordisk